Renal osteodystrophy

  • Francisco Llach
  • Francisco Velasquez-Forero


In this chapter the term ‘renal osteodystrophy’ will be used in a generic sense to include all the clinical syndromes of skeletal disease and altered calcium (Ca) and phosphorus (P) homeostasis resulting from chronic renal failure (CRF). The skeletal pathology can include osteitis fibrosa and other features of secondary hyperparathyroidism, osteomalacia, aplastic or adynamic bone disease, osteoporosis, osteosclerosis and, in children, retardation of growth. Emphasis will be placed on the clinical manifestations of these syndromes that occur in patients on maintenance hemodialysis with a consideration of diagnosis, prevention and management.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Avioli LV. Collagen metabolism, uremia and bone. Kidney Int. 1973;4:105.PubMedGoogle Scholar
  2. 2.
    Mirahmadi KS, Coburn JW, Bluestone R. Calcific periarthritis and hemodialysis. J Am Med Assoc. 1973;229:548–9.Google Scholar
  3. 3.
    Hardouin P, Lecomte-Houcke M, Flipo RM et al. Current aspects of osteoarticular pathology in patients undergoing hemodialysis: study of 80 patients. Part 2. Laboratory and pathologic analysis. Discussion of the pathogenic mechanism. J Rheumatol. 1987;14:784–7.PubMedGoogle Scholar
  4. 4.
    Llach F, Pederson JA. Acute joint syndrome and maintenance hemodialysis. Proc Clin Dial Transplant. Forum 1979;9:17–22.PubMedGoogle Scholar
  5. 5.
    Massry SG, Popovtzer MM, Coburn JW. Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching following subtotal parathyroidectomy. N Engl J Med. 1968;279:697.PubMedGoogle Scholar
  6. 6.
    Massry SG, Popovtzer MM, Coburn JW, Makoff DL, Maxwell MH, Kleeman CR. Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. N Engl J Med. 1968;279:697–700.PubMedGoogle Scholar
  7. 7.
    Gilchrest B et al. Relief of uremic pruritus with ultraviolet phototherapy. N Engl J Med. 1977;297:136.PubMedGoogle Scholar
  8. 8.
    Pederson JA, Matter BJ, Czerwinski A, Llach F. Relief of idiopathic generalized pruritus in dialysis patients with activated oral charcoal. Ann Intern Med. 1980;93:446.PubMedGoogle Scholar
  9. 9.
    De Marchi S et al. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med. 1992; 326:969.PubMedGoogle Scholar
  10. 10.
    Stockenhuber F et al. Increased plasma histamine levels in uraemic pruritus. Clin Sci. 1990;79:477.PubMedGoogle Scholar
  11. 11.
    Berlyne GM. Microcrystalline conjunctival calcification in renal failure: a useful clinical sign. Lancet. 1968;2:366.PubMedGoogle Scholar
  12. 12.
    Berlyne GM, Shaw AG. Red eyes in renal failure. Lancet. 1967;1:4.PubMedGoogle Scholar
  13. 13.
    Schott GD, Wills MR. Muscle weakness in osteomalacia. Lancet. 1976;1:626.PubMedGoogle Scholar
  14. 14.
    Baker LRI, Ackrill P, Cattell WR. Iatrogenic osteomalacia and myopathy due to phosphate depletion. Br Med J. 1974;3:150.PubMedGoogle Scholar
  15. 15.
    Smith R, Stern G. Myopathy, osteomalacia and hyperparathyroidism. Brain. 1967;90:593.PubMedGoogle Scholar
  16. 16.
    Coburn JW, Nebeker HG, Hercz G et al. Role of aluminum accumulation in the pathogenesis of renal osteodystrophy. In: Robinson RR, editor. Nephrology, vol. II. New York: Springer-Verlag, 1984;1383–95.Google Scholar
  17. 17.
    Brickman AS, Sherrard DJ, Jowsey J. 1,25-Dihydroxycholecalciferol: effect on skeletal lesions and plasma parathyroid hormone in uremic osteodystrophy. Arch Intern Med. 1974;134:883.PubMedGoogle Scholar
  18. 18.
    Kanis JA, Cundy T, Earnshaw M et al. Treatment of renal bone disease with lα-hydroxylated derivatives of vitamin D3: clinical, biochemical, radiographic and histological responses. Q J Med (new series). 1979;48:289–322.Google Scholar
  19. 19.
    Cirincione R, Baker B. Tendon rupture with secondary hyperparathyroidism. J Bone Joint Surg. 1975;57:852.PubMedGoogle Scholar
  20. 20.
    Preston F, Adicoff A. Hyperparathyroidism with avulsion of three major tendons. N Engl J Med. 1962;266:968.PubMedGoogle Scholar
  21. 21.
    Murphy KJ, McPhee I. Tears of major tendons in chronic acidosis with elastosis. J Bone Joint Surg. 1971;53:510.Google Scholar
  22. 22.
    Selye H. Calciphylaxis. Chicago, IL: University of Chicago Press, 1962.Google Scholar
  23. 23.
    Anderson DC, Stewart WK, Piercy DM. Calcifying panniculitis with fat and skin necrosis in a case of uremia with autonomous hyperparathyroidism. Lancet. 1968;2:323–5.PubMedGoogle Scholar
  24. 24.
    Coates T, Kirkland GS, Dymock RB et al. Ischemic tissue necrosis (calciphylaxis) in renal failure. Am J Kidney Dis. 1998;32:384–91.PubMedGoogle Scholar
  25. 25.
    Gipstein RM, Coburn JW, Adams DA et al. Calciphylaxis in man. Arch Intern Med. 1976;136:1273–80.PubMedGoogle Scholar
  26. 26.
    Bleyer AJ, Choi M, Igwenezie B, de la Torre E, White WL. A case-control study of proximal calciphylaxis. Am J Kidney Dis. 1998;32:376–83.PubMedGoogle Scholar
  27. 27.
    Katz AL, Hampers CL, Merrill JP. Secondary hyperparathyroidism and renal osteodystrophy in chronic renal failure: analysis of 195 patients, with observations on the effects of chronic dialysis, kidney transplantation and subtotal parathyroidectomy. Medicine. 1969;48:333–74.PubMedGoogle Scholar
  28. 28.
    Ross CN, Casidy MJD, Thompson M, Russel Jones R, Rees AJ. Proximal cutaneous necrosis associated with small vessel calcification in renal failure. Q J Med. 1991;289:443–50.Google Scholar
  29. 29.
    Massry SG, Coburn JW, Hartenbower DL et al. Mineral content of human skin in uremia. Effect of secondary hyperparathroidism and hemodialysis. Proc Eur Dial Transplant Assoc. 1970;7:146–8.Google Scholar
  30. 30.
    Massry SG, Coburn JW, Hartenbower DL et al. The effect of calcemic disorders and uremia or the mineral content of the skin. Israel J Med Sci. 1971;7:514–17.PubMedGoogle Scholar
  31. 31.
    Campisol JM, Almirall J, Martin E, Torras A, Revert L. Calcium-carbonate-induced calciphylaxis. Nephrology. 1989;51:549–50.Google Scholar
  32. 32.
    McAuley K, Devereux F, Walker R. Calciphylaxis in two non-compliant patients with end-stage renal failure. Nephrol Dial Transplant. 1997;12:1061–3.PubMedGoogle Scholar
  33. 33.
    Llach F, Goldblatt M, Freundlich RE, Gannesh M, Griffith WH, Yudd M. The evolving pattern of calcific uremic arteriolopathy (calciphylaxis). J Am Soc Nephrol. 2000;Google Scholar
  34. 34.
    Hafner J, Keusch G, Wahl C et al. Uremic small artery disease with medial calcification and intimal hypertrophy (socalled calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol. 1995;33:954–62.PubMedGoogle Scholar
  35. 35.
    Mehls O, Ritz E, Krempien B. Roentgenological signs in the skeleton of uremic children. An analysis of the anatomical principles underlying the roentgenological changes. Pediatr Radiol. 1973;1:183.PubMedGoogle Scholar
  36. 36.
    Mehls O. Renal osteodystrophy in children: etiology and clinical aspects. In: Fine RN, Gruskin AB, editors. Endstage Renal Disease in Children. Philadelphia: Saunders, 1984:227–50.Google Scholar
  37. 37.
    Stanbury SW. The role of vitamin D in renal bone disease. Clin Endocrinol. 1977;7:25S.Google Scholar
  38. 38.
    Parfitt AM. Clinical and radiographic manifestations of renal osteodystrophy. In: David DS, editor. Calcium Metabolism in Renal Failure and Nephrolithiasis. New York: John Wiley, 1977:150–90.Google Scholar
  39. 39.
    Scharer K et al. Growth in children with chronic renal failure. Kidney Int. 1978;13 (Suppl.):S68.Google Scholar
  40. 40.
    Chantler C, Danckerwolcke RA, Brunner FP et al. Combined report on regular dialysis and transplantation of children in Europe. Proc Eur Dial Transplant Assoc. 1979;16:74–104.Google Scholar
  41. 41.
    Simmons JM, Wilson CJ, Potter DE, Holliday MA. Relation of caloric deficiency to growth failure in children on hemodialysis and the growth response to caloric supplementation. N Engl J Med. 1971;285:653–6.PubMedGoogle Scholar
  42. 42.
    Chantler C, Holliday M. Growth in children with renal disease, with special reference to the effects of caloric malnutrition: a review. Clin Nephrol. 1973;1:230.PubMedGoogle Scholar
  43. 43.
    McSherry E, Morris RC. Attainment and maintenance of normal growth status with alkali therapy in infants and children with classic renal tubular acidosis (RTA). J Clin Invest. 1978;61:509–27.PubMedGoogle Scholar
  44. 44.
    Saenger P, Wiedmann E, Schwartz E. Somatomedin and growth after renal transplantation. Pediatr Res. 1974;8:163.PubMedGoogle Scholar
  45. 45.
    Chesney RW, Moorthy A, Eisman JA et al. Increased growth after long-term oral 1,25-vitamin D3 in childhood renal osteodystrophy. N Engl J Med. 1978;298:238–42.PubMedGoogle Scholar
  46. 46.
    Tonshoff B, Mehls O, Heinrich U, Blum WF, Ranke MB, Schauer A. Growth-stimulating effect of recombinant human growth hormone in children with end-stage renal disease. J Pediatr. 1990;116:561–6.PubMedGoogle Scholar
  47. 47.
    Blum WF, Ranke MB, Kietzmann K et al. Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia. Pediatr Nephrol. 1991;5:539–44.PubMedGoogle Scholar
  48. 48.
    Eidemak I, Feldt-Rasmussen B, Strandgaard S, Kanstrup IL, Nielsen SL. Insulin resistance is present in moderate uraemia and correlated to the maximal aerobic work capacity. J Am Soc Nephrol. 1992;3:281.Google Scholar
  49. 49.
    Stivelman JC. Refractoriness to recombinant human epoetin treatment. In: Nissenson AR, Fine RN, editors. Dialysis Therapy. Philadelphia: Mosby-Year Book, 1993:236.Google Scholar
  50. 50.
    Coburn JW, Massry SG, DePalma JS, Shinaberger JH. Rapid appearance of hypercalcemia with initiation of hemodialysis. J Am Med Assoc. 1969;210:2276.Google Scholar
  51. 51.
    Mazzaferro S, Coen G, Bandini S et al. Mitral annulus calcification in uremia. Nephrol Dial Transplant. 1993; 8:335–40.PubMedGoogle Scholar
  52. 52.
    Bogin E, Massry SG, Harary I. Effect of parathyroid hormone on heart cells. J Clin Invest. 1981;67:1215.PubMedGoogle Scholar
  53. 53.
    London GM, Fabiani F, Marchais SJ et al. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int. 1987;31:973–80.PubMedGoogle Scholar
  54. 54.
    London GM, de Vernejoul MC, Fabiani F et al. Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int. 1987;32:900–7.PubMedGoogle Scholar
  55. 55.
    Marchais SJ, Guerin AP, London AM, Llach F, London GM. Long-term effects of parathyroidectomy on left ventricular function in hemodialysis patients. Blood Purif. 1992;2:155–62.Google Scholar
  56. 56.
    Llach F, Felsenfeld AJ, Coleman M, Keveney J Jr, Pederson JA, Medlock T. The natural course of dialysis osteomalacia. Kidney Int. 1986;29:574–9.Google Scholar
  57. 57.
    Roth A, Nogues C, Galle P et al. Multiorgan aluminum deposits in a chronic haemodialysis patient. Electron microscope and microprobe studies. Virchows Arch (Pathol Anat). 1984;405:131–40.Google Scholar
  58. 58.
    London G, deVernejoul MC, Fabiani F et al. Association between aluminum accumulation and cardiac hypertrophy in hemodialyzed patients. Am J Kidney Dis. 1989;13: 75–83.PubMedGoogle Scholar
  59. 59.
    Ribeiro S, Ramos A, Brandero A, Rebelo JR, Villa-Lobos A, Rebeiro F. Cardiac valve calcification in hemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant. 1998;13:2037–40.PubMedGoogle Scholar
  60. 60.
    Braun J, Olendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996;27:394–401.PubMedGoogle Scholar
  61. 61.
    Llach F, Massry SG. On the mechanism of the prevention of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab. 1985;61:601–6.PubMedGoogle Scholar
  62. 62.
    Walling MW. Intestinal Ca and phosphate transport: differential responses of vitamin D metabolites. Am J Physiol. 1977;133:3488.Google Scholar
  63. 63.
    Coburn JW, Brickman AS, Sherrard DJ. Clinical efficacy of 1,25 dihydroxyvitamin D3 in renal osteodystrophy. In: Norman AW, Schaefer K, Coburn JW, editors. Vitamin D. Biochemical, Chemical and Clinical Aspects Related to Calcium Metabolism. Berlin: de Gruyter, 1977:657.Google Scholar
  64. 64.
    Gallieni M, Brancaccio D, Padovese P et al., Italian Group for the Study of Intravenous Calcitriol. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int. 1992;42:1191–8.PubMedGoogle Scholar
  65. 65.
    Massry SG, Coburn JW, Popovtzer MM. Secondary hyperparathyroidism in chronic renal failure: the clinical spectrum in uremia, during hemodialysis and after renal transplantation. Arch Intern Med. 1969;124:431.PubMedGoogle Scholar
  66. 66.
    Coburn JW, Brickman AS, Massry SG. Medical treatment in primary and secondary hyperparathyroidism. Semin Drug Treat. 1972;2:117.PubMedGoogle Scholar
  67. 67.
    Kopple JD, Coburn JW. Metabolic studies of low protein diets in uremia. II. Calcium, phosphorus and magnesium. Medicine. 1973;52:597.PubMedGoogle Scholar
  68. 68.
    Wiegmann TB, Kaye M. Malabsorption of calcium and phosphate in chronic renal failure. 32P and 45Ca studies in dialysis patients. Clin Nephrol. 1990;34:35–41.PubMedGoogle Scholar
  69. 69.
    Coburn JW, Popovtzer MM, Massry SG, Kleeman CR. The physiochemical state and renal handling of divalent ions in chronic renal failure. Arch Intern Med. 1969;124:302.PubMedGoogle Scholar
  70. 70.
    Walser M. The separate effects of hyperparathyroidism, hypercalcemia of malignancy, renal failure and acidosis on the state of calcium phosphate and other ions in plasma. J Clin Invest. 1962;41:1454.PubMedGoogle Scholar
  71. 71.
    Raman A, Chong YK, Sreenevasan G. Effects of varying dialysate calcium concentration on the plasma calcium fractions in patients on dialysis. Nephron. 1976;16:181.PubMedGoogle Scholar
  72. 72.
    Wing AJ, Curtis JR, Eastwood JB. Transient and persistent hypercalcaemia in patients treated by maintenance haemodialysis. Br Med J. 1968;4:150.PubMedGoogle Scholar
  73. 73.
    Messner RP et al. The effect of hemodialysis, vitamin D, and renal homotransplantation on the calcium malabsorption of chronic renal failure. J Lab Clin Med. 1969;74:472.PubMedGoogle Scholar
  74. 74.
    Morton AR, Hercz G. Hypercalcemia in dialysis patients: comparison of diagnostic methods. Dial Transplant. 1991;20:661–7.Google Scholar
  75. 75.
    Shimada H, Makamura M, Marumo F. Influence of aluminum on the effect of 1(OH)D3 on renal osteodystrophy. Nephron. 1983;35:163.PubMedGoogle Scholar
  76. 76.
    Slatopolsky E, Weerts C, Lopez-Hilker S et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med. 1986;315:157–61.PubMedGoogle Scholar
  77. 77.
    Llach F. Effects of renal failure and dialysis on divalent ion metabolism. In: Brenner BM, Stein JH, editors. Divalent Ion Homeostasis, Vol. 11: Contemporary Issues in Nephrology. New York: Churchill Livingstone, 1983:291–317.Google Scholar
  78. 78.
    Schaefer K, Scheer J, Asmus G, Umlauf E, Hagemann J, von Herrath D. The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant. 1991;6:171–5.Google Scholar
  79. 79.
    Papadimitriou M, Gingell J, Chisholm G. Hypercalcemia from calcium ion exchange resins in patients on regular hemodialysis. Lancet. 1968;2:948.PubMedGoogle Scholar
  80. 80.
    Barbour GL, Coburn JW, Slatopolsky E, Norman AW, Horst RL. Hypercalcemia in an anephric patient with sarcoidosis, evidence for extrarenal generation of 1,25 dihydroxyvitamin D. N Engl J Med. 1981;305:440–6.PubMedGoogle Scholar
  81. 81.
    Felsenfeld AJ, Drezner MK, Llach F. Hypercalcemia and elevated calcitriol in a maintenance dialysis patient with tuberculosis. Arch Intern Med. 1986;146:1941–4.PubMedGoogle Scholar
  82. 82.
    Schmulen AC, Lerman M, Pak CYC et al. Effect of 1,25-dihydroxyvitamin D3 therapy on jejunal absorption of magnesium in patients with chronic renal failure. Am J Physiol. 1980;238:349–55G.Google Scholar
  83. 83.
    Coburn JW, Hartenbower DL, Brickman AS. Intestinal absorption of calcium, magnesium, and phosphorus in chronic renal insufficiency. In: David DS, editor. Calcium Metabolism in Renal Failure and Nephrolithiasis. New York: John Wiley, 1977:77–109.Google Scholar
  84. 84.
    Brannan PG et al. Magnesium absorption in the human small intestine: results in patients with absorptive hypercalciuria. J Clin Invest. 1976;57:1412.PubMedGoogle Scholar
  85. 85.
    Alfrey AC, Solomons CC, Ciricillo J, Miller NL. Extraosseous calcification. Evidence for abnormal pyrophosphate metabolism in uremia. J Clin Invest. 1976;57:692.PubMedGoogle Scholar
  86. 86.
    Wallach S. Relation of magnesium to osteoporosis and calcium urolithiasis. Magn Trace Elem. 1991;10:281–6.Google Scholar
  87. 87.
    Guillot AP, Hood VL, Runge CF, Gennari FJ. The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron. 1982;30:114–17.PubMedGoogle Scholar
  88. 88.
    Stewart WK, Fleming LW. The effects of dialysate magnesium on plasma and erythocyte magnesium and potassium concentrations during maintenance haemodialysis. Nephron. 1973;10:221–31.Google Scholar
  89. 89.
    O’Donovan R, Baldwin D, Hammer M, Moniz C. Substitution of aluminum salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet. 1986;1:880.PubMedGoogle Scholar
  90. 90.
    Freeman RM. The role of magnesium in the pathogenesis of azotemic hypothermia. Proc Soc Exp Biol Med. 1971; 137:1069.PubMedGoogle Scholar
  91. 91.
    Freeman RM, Lawton RL, Chamberlain MA. Hard water syndrome. N Engl J Med. 1967;276:1113.PubMedGoogle Scholar
  92. 92.
    Habener JF, Potts JT Jr. Relative effectiveness of magnesium and calcium on the secretion and biosynthesis of parathyroid hormone in vitro. Endocrinology. 1976;98:197.PubMedGoogle Scholar
  93. 93.
    Mennes P, Rosenbaum R, Martin KJ, Slatopolsky E. Hypomagnesemia and impaired parthyroid hormone secretion in chronic renal disease. Ann Intern Med. 1978; 88:206.PubMedGoogle Scholar
  94. 94.
    Price PA et al. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone Gla protein in the plasma of normal subjects and patients with bone disease. J Clin Invest. 1980;66:878.PubMedGoogle Scholar
  95. 95.
    Slovid DM et al. Clinical evaluation of bone turnover by serum osteocalcin measurements. Calcif Tissue Int. 1982;34:S15.Google Scholar
  96. 96.
    Charhon SA, Delmas PD, Malaval L et al. Serum bone Glaprotein in renal osteodystrophy: comparison with bone histomorphometry. J Clin Endocrinol Metab. 1986;63:892–7.PubMedGoogle Scholar
  97. 97.
    Epstein S, Traberg H, Raja R et al. Serum and dialysate osteocalcin levels in hemodialysis and peritoneal dialysis patients and after renal transplantation. J Clin Endocrinol Metab. 1985;60:1253–6.PubMedGoogle Scholar
  98. 98.
    Coen G, Mazzaferro S, Ballanti P et al. Procollagen type I C-terminal extension peptide in predialysis chronic renal failure. Am J Nephrol. 1992;12:246–51.PubMedGoogle Scholar
  99. 99.
    Felsenfeld A, Llach F. Parathyroid gland function in chronic renal failure. Kidney Int. 1993;43:771–89.PubMedGoogle Scholar
  100. 100.
    Nussbaum SR, Potts JT Jr. Immunoassays for parathyroid hormone 1–84 in the diagnosis of hyperparathyroidism. J Bone Mineral Res. 1991;6 (Supp1.2):S43–50.Google Scholar
  101. 101.
    Lepage R, Roy L, Brossard JH et al. A non (1–84) circulating parathyroid hormone fragment interferes significantly with intact PTH commercial assay measurement in uremic samples. Clin Chem. 1998;44:805–9.PubMedGoogle Scholar
  102. 102.
    John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jupner H. A novel immunorediometric assay detect full length human PTH but not amino-terminally truncated segments: implications for PTH measurement in renal failure. J Clin Endocrinol Metab. 1999;84:4287–90.PubMedGoogle Scholar
  103. 103.
    Slatopolsky E, Finch J, Clay P et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 2000;58:753–51.PubMedGoogle Scholar
  104. 104.
    Milliner DS, Ott SM, Nebeker HG. Deferroxamine infusion test for diagnosis of aluminum related osteomalacia. Ann Intern Med. 1984;101:775–9.PubMedGoogle Scholar
  105. 105.
    Cannata JB, Diaz Lopez JB. Insights into the complex aluminium and iron relationship. Nephrol Dial Transplant. 1991;6:605–7.PubMedGoogle Scholar
  106. 106.
    Meema HE, Oreopoulos DG, Rabinovich S. Periosteal new bone formation (periosteal neostasis) in renal osteodystrophy. Radiology. 1974;110:513.PubMedGoogle Scholar
  107. 107.
    Doyle FH. Radiological patterns of bone disease associated with renal glomerular failure in adults. Br Med Bull. 1972;28:220.PubMedGoogle Scholar
  108. 108.
    Meema HE, Rabinovich S, Meema S, Lloyd GJ, Oreopoulos DG. Improved radiological diagnosis of azotemic osteodystrophy. Radiology. 1972;102:1–10.PubMedGoogle Scholar
  109. 109.
    Ritz E, Prager P, Krempien B. Skeletal x-ray findings and bone histology in patients on hemodialysis. Kidney Int. 1978;13:316.PubMedGoogle Scholar
  110. 110.
    Eastwood JB, Bordier PhJ, De Wardener H. Some biochemical, histological, radiological and clinical features of renal osteodystrophy. Kidney Int. 1973;4:128.PubMedGoogle Scholar
  111. 111.
    Glassford D, Remmers AR, Sarles H. Hyperparathyroidism in the maintenance dialysis patient. Surg Gynecol Obstet. 1976;142:328.PubMedGoogle Scholar
  112. 112.
    Tatler GL, Baillod RA, Varghese Z et al. Evolution of bone disease over 10 years in 135 patients with terminal renal failure. Br Med J. 1973;4:315–19.PubMedGoogle Scholar
  113. 113.
    Prager P, Singer R, Ritz E, Krempien B. Diagnostischer Stellenwert der Lamina dura dentium beim sekundaren Hyperparathyreoidismus. Fortschr Rontgenstrl. 1978;129: 237.Google Scholar
  114. 114.
    Meema HE, Meema S. Comparison of microradioscopic and morphometric findings in the hand bones with densitometric finding in the proximal radius in thyrotoxicosis and in renal osteodystrophy. Invest Radiol. 1972;7:88.PubMedGoogle Scholar
  115. 115.
    Ellis K, Hochstim RJ. The skull in hyperparathyroid bone disease. Am J Roentgenol. 1960;83:732.Google Scholar
  116. 116.
    Owen J, Parnell A, Keir M et al. Critical analysis of the use of skeletal surveys in patients with chronic renal failure. Clin Radiol. 1988;39:578–82.PubMedGoogle Scholar
  117. 117.
    Chalmers J, Conacher WD, Gardner DL, Scott PJ. Osteomalacia — a common disease in elderly women. J Bone Joint Surg. 1967;49B:403.Google Scholar
  118. 118.
    Ritz E, Krempien B, Mehls O, Malluche HH. Skeletal abnormalities in chronic renal insufficiency before and during maintenance hemodialysis. Kidney Int. 1973;4:116.PubMedGoogle Scholar
  119. 119.
    Moriniere P, Cohen-Solal M, Belbrik S et al. Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting Al(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum. Nephron. 1989;53:93–101.PubMedGoogle Scholar
  120. 120.
    Kessler M, Azoulay E, Netter P, Mayeux D, Pere P, Gaucher A. Arthropathie du dialyse: resultats d ’une etude multicentrique realisee chez 171 malades hemodialyses depuis plus de 10 ans. In: Gaucher A, Pourel J, Netter P, Kessler M, editors. Actualites en physiopathologie et pharmacologie acticulairs. Paris: Masson, 1989:272–9.Google Scholar
  121. 121.
    Norfray J, Calenoff L, DelGreco F, Krumlovsky F. Renal osteodystrophy in patients on hemodialysis as reflected in the bony pelvis. Am J Roentgenol. 1975;125:352.Google Scholar
  122. 122.
    Parfitt AM. Soft tissue calcification in uremia. Arch Intern Med. 1969;124:544.PubMedGoogle Scholar
  123. 123.
    Jonhson C, Graham CB, Curtis FK. Roentgenographic manifestations of chronic renal disease treated by pedic hemodialysis. Am J Radium Ther Nucl Med. 1967;101: 915–26.Google Scholar
  124. 124.
    Benhamou CL, Rouchon JP, Geslin N, Pierre D, Viala JF, Barthez JP. Arthropathies des membres chez les insuffisants renaux dialyses. Presse Med. 1987;16:119–22.PubMedGoogle Scholar
  125. 125.
    Chou CT, Wassertein A, Schumacher HR, Fernandez P. Muskuloskeletal manifestations in hemodialysis patients. J Rheumatol. 1985;12:1149–53.PubMedGoogle Scholar
  126. 126.
    Rubin LA, Fam AG, Rubenstein J, Campbell J, Saiphoo C. Erosive azotemic osteoarthropathy. Arthritis Rheum 1984;27:1086–94.PubMedGoogle Scholar
  127. 127.
    Bardin T, Vasseur M, de Vernejoul MC et al. Etude prospective de 1 ’atteinte articulair des malades hemodialyses depuis plus de 10 ans. Rev Rheum. 1988;55:131–4.Google Scholar
  128. 128.
    Ritz E, Mehls O, Bommer J. Vascular calcifications under maintenance hemodialysis. Klin Wochenschr. 1977;55:375.PubMedGoogle Scholar
  129. 129.
    Meema HE et al. Arterial calcifications in severe chronic renal disease and their relationship to dialysis treatment, renal transplant, and parathyroidectomy. Radiology. 1976; 121:315.PubMedGoogle Scholar
  130. 130.
    DeFrancisco AM, Ellis HA, Owen JP et al. Parathyroidectomy in chronic renal failure. Q J Med. 1985;55: 289–315.PubMedGoogle Scholar
  131. 131.
    Zins B, Zingraff J, Basile C et al. Tumoral calcifications in hemodialysis patients: possible role of aluminum intoxication. Nephron. 1992;60:260–7.PubMedGoogle Scholar
  132. 132.
    Kainberger F, Traindl O, Baldt M et al. Renale Osteodystrophie: Spektrum der Rontgensymptomatik bei modernen Formen der Nierentransplantation und Dauerdialysetherpie. Rofo Fortschr geb Rontgenstr Neuen Bildgeb Verfahr. 1992;157:501–5.PubMedGoogle Scholar
  133. 133.
    Llach F, Coburn JW. Renal osteodystrophy and maintenance dialysis. In: Maher JF, editor. Replacement of Renal Function by Dialysis. Dordrecht: Kluwer, 1989:911–52.Google Scholar
  134. 134.
    Drueke TB. A clinical approach to the uraemic patient with extraskeletal calcifications. Nephrol Dial Transplant. 1996;11:37–42.PubMedGoogle Scholar
  135. 135.
    Contiguglia S, Alfrey AC, Miller NL. Nature of soft tissue calcification in uremia. Kidney Int. 1973;4:229.PubMedGoogle Scholar
  136. 136.
    Kuzela D, Huffer WE, Conger JD. Soft tissue calcification in chronic dialysis patients. Am J Pathol. 1977;86:403.PubMedGoogle Scholar
  137. 137.
    Conger JD, Hammond WS, Alfrey AC, Contiguglia SR, Stanford RE, Huffer WE. Pulmonary calcification in chronic dialysis patients. Clinical and pathologic studies. Ann Intern Med. 1975;83:330–6.PubMedGoogle Scholar
  138. 138.
    Davis B, Poulose K, Reba R. Scanning for uremic pulmonary calcifications. Ann Intern Med. 1976;85:132.PubMedGoogle Scholar
  139. 139.
    Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001; 12:2131–8.PubMedGoogle Scholar
  140. 140.
    Llach F. Calcification: dealing with another risk factor in patients with renal failure. Semin Dial. 1999;12:293–5.Google Scholar
  141. 141.
    Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827–32.PubMedGoogle Scholar
  142. 142.
    Achenback S, Moshage W, Rogers D, Nossen J, Daniel WG. Value of electron-beam computed tomography for the noninvasive detection of high-grade coronary artery stenoses and occlusions. N Engl J Med. 1998;339:1964–71.Google Scholar
  143. 143.
    Goodman WG, Goldin J, Kuzon BD et al. Coronary artery calcification in young adults with ESRD who are undergoing dialysis. N Engl J Med. 2000;342:1478–83.PubMedGoogle Scholar
  144. 144.
    Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15:1014–21.PubMedGoogle Scholar
  145. 145.
    Rostand SG. Coronary heart disease in chronic renal insufficiency: some management considerations. J Am Soc Nephrol. 2000;11:1948–56.PubMedGoogle Scholar
  146. 146.
    Parkinson IS, Feest TG, Ward MK. Fracturing dialysis osteodystrophy and dialysis encephalopathy: an epidemiological survey. Lancet. 1979;1:406.PubMedGoogle Scholar
  147. 147.
    Mora-Palma FJ, Lorenzo Sellares V, Ellis HL, Ward MK, Kerr D. Osteomalacia in chronic renal failure before dialysis. Proc Eur Dial Transplant Assoc. 1983;19:188–94.PubMedGoogle Scholar
  148. 148.
    Ward MK, Feest TG, Ellis HA. Osteomalacic dialysis osteodystrophy: evidence for a waterborne etiological agent, probably aluminum. Lancet. 1978;1:841.PubMedGoogle Scholar
  149. 149.
    Llach F, Nikakhtar B. Current advances in the therapy of secondary hyperparathyroidism and osteitis fibrosa. Miner Electrolyte Metab. 1991;17:250–5.PubMedGoogle Scholar
  150. 150.
    Maloney NA, Ott SM, Alfrey AC, Coburn JW, Sherrard DJ. Histologic quantitation of aluminum in iliac bone from patients with renal failure. J Lab Clin Med. 1982;99:206–16.PubMedGoogle Scholar
  151. 151.
    Hodsman AB, Sherrard DJ, Alfrey AC et al. Bone aluminum and histomorphometric features of renal osteodystrophy. J Clin Endocrinol Metab. 1982;54:539–46.PubMedGoogle Scholar
  152. 152.
    Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in end-stage renal failure — an evolving disorder. Kidney Int. 1993;43:436–42.PubMedGoogle Scholar
  153. 153.
    Rodriguez M, Lorenzo V, Felsenfeld AJ, Llach F. Effect of parathyroidectomy on aluminum toxicity and azotemic bone disease in the rat. J Bone Miner Res. 1990;5:379–85.PubMedGoogle Scholar
  154. 154.
    Amann K, Gross ML, London, GM, Ritz E. Hyperphosphatemia — a silent killer of patients with renal failure? Nephrol Dial Transplant. 1999;14:2085–7.PubMedGoogle Scholar
  155. 155.
    Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. A J Kidney Dis. 1998;31:607–17.Google Scholar
  156. 156.
    Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate of differences between facilities. Am J Kidney Dis. 1990;15:458–82.PubMedGoogle Scholar
  157. 157.
    Massry SG, Kopple JD. Requirements for calcium, phosphorus, and vitamin D. In: Mitch WE, Klahr S, editors. Nutrition and the Kidney, Boston: Little, Brown, 1993:96.Google Scholar
  158. 158.
    Kopple JD, Coburn JW. Metabolic studies of low protein diets in uremia. II. Calcium, phosphorus and magnesium. Medicine. 1973;52:597–607.PubMedGoogle Scholar
  159. 159.
    Schoenfeld P, Henry R, Laird N. Assessment of nutritional status of the National Cooperative Dialysis Study population. Kidney Int. 1980;23:580–8.Google Scholar
  160. 160.
    Blumenkrantz MJ, Kopple JD, Moran J, Coburn JW. Metabolic balance studies and dietary protein requirements in patients undergoing continuous peritoneal dialysis. Kidney Int. 1982;21:849–58.PubMedGoogle Scholar
  161. 161.
    Schiller L, Santa Ana CA, Sheikh M, Emmett M, Fordtran J. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med. 1989;320:1110–13.PubMedGoogle Scholar
  162. 162.
    Rosenbaum DP, Holmes-Farley SR, Mandeville WH, Pitruzzello M, Goldberg DI. Effect of Renagel, a nonabsorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol Dial Transplant. 1997;12:961–4.PubMedGoogle Scholar
  163. 163.
    Burke SK, Slatopolsky EA, Goldberg DI. Renagel®, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant. 1997;12:1640–4.PubMedGoogle Scholar
  164. 164.
    Chertow GM, Burke SK, Lazarus JM et al. A phase II trial of poly(allylamine hydrochloride) (Renagel) in hemodialysis patients. Am J Kidney Dis. 1997;1:66–71.Google Scholar
  165. 165.
    Goldberf DI, Dillon MA, Slatopolsky EA et al. Effect of Renagel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant. 1998;13:2303–10.Google Scholar
  166. 166.
    Raggi P, Burke SK, Dillon MA, Amin N, Bommer J, Chertow GM. Sevelamer attenuates the progression of coronary artery and aortic calcifications compared with calcium-based phosphate binders. J Am Soc Nephrol. 2001; 12:239A.Google Scholar
  167. 167.
    Clarkson EM, McDonald SJ, De Wardener H. The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin Sci. 1966;30:425–38.PubMedGoogle Scholar
  168. 168.
    Fournier A, Moriniere P, Sebert JL et al. Calcium carbonate, an aluminum free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism. Kidney Int. 1986;29(Supp1.18):S114–19.Google Scholar
  169. 169.
    Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Windus D, Delmez J. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Eng! J Med. 1986;315:157–61.Google Scholar
  170. 170.
    Hercz G, Kraut JA, Andress DL. Use of calcium carbonate as a phosphate binder in dialysis patients. Miner Electrolyte Metab. 1986;12:314.PubMedGoogle Scholar
  171. 171.
    Argiles A, Kerr PG, Canaud B, Flavier JL, Mion C. Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int. 1993;43:630–40.PubMedGoogle Scholar
  172. 172.
    Winney RJ, Cowie JF, Robson JS. The role of plasma aluminum in the detection and prevention of aluminum toxicity. Kidney Int. 1986;29(Supp1.18):S91–5.Google Scholar
  173. 173.
    Salusky IB, Foley J, Nelson P, Goodman WG. Aluminum accumulation from recommended doses of aluminum hydroxide in dialyzed children. N Engl J Med. 1991;324: 527–31.PubMedGoogle Scholar
  174. 174.
    Harter HR, Laird NM, Teehan BP. Effects of dialysis prescription on bone and mineral metabolism: The National Cooperative Dialysis Study. Kidney Int. 1983;23(Supp1.13): S73–9.Google Scholar
  175. 175.
    O’Donovan R, Baldwin D, Hammer M, Moniz C. Substitution of aluminum salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet. 1986;1:880–9.PubMedGoogle Scholar
  176. 176.
    Sheikh M, Maguire M, Emmett M, Nicar M, Schiller L, Fordtram J. Reduction of dietary phosphorus absorption by phosphorus binders. J Clin Invest. 1989;83:66–73.PubMedGoogle Scholar
  177. 177.
    Cushner HM, Copley J, Lindberg J, Foulks C. Calcium citrate, a non aluminum containing phosphate binding agent for treatment of CRF. Kidney Int. 1988;35:95–9.Google Scholar
  178. 178.
    Bro S, Rasmussen RA, Handberg J, Olgaard K, Feldt-Rasmussen B. Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. Am J Kidney Dis. 1998;31:257–62.PubMedGoogle Scholar
  179. 179.
    Macia M, Coronel F, Navarro JF et al. Calcium salts of ketoamino acids, a phosphate binder alternative for patients on CAPD. Clin Nephrol. 1997;48:181–4.PubMedGoogle Scholar
  180. 180.
    Nebeker HG, Schneider HW, Coburn JW. A non-aluminum containing phosphate binder: polyuronic acid. Kidney Int. 1985;27:147 (abstract).Google Scholar
  181. 181.
    Joy MS, Finn WF, Lanthanum Study Group. Results of a randomized, phase HI, dose-titration, parallel group study of lanthanum carbonate for reduction and maintenance of serum phosphate in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:388A.Google Scholar
  182. 182.
    Behets GJ, Dams G, Damment S, D’Haese PC, De Broe ME. An assessment of the effect of lanthanum on bone in a chronic renal failure rat model. J Am Soc Nephrol. 2001;12:740A.Google Scholar
  183. 183.
    Kaye M, Turner M, Ardila M, Wiegmann Th, Hodsman AB. Aluminum and phosphate. Kidney Int. 1988;33(Supp1.24): 5172–4.Google Scholar
  184. 184.
    Hou SH, Zhao J, Ellman CF et al. Calcium and phosphorus fluxes during hemodialysis with a low calcium dialysate. Am J Kidney Dis. 1991;18:217–24.PubMedGoogle Scholar
  185. 185.
    Shinaberger JH, Miller JH, Gardner PW. Characteristics of available dialyzers. In: Nissenson AR, Fine RN, Genile D, editors. Norwalk, CT: Appleton Century Crofts, 1984: 275–87.Google Scholar
  186. 186.
    Albertini BV, Miller JH, Gardner PW, Shinaberger JH. High flux hemodiafiltration: under six hours/week treatment. Trans Am Soc Artif Internal Organs. 1984;30:227–31.Google Scholar
  187. 187.
    Delmez JA, Slatopolsky E, Martin KJ, Gearing BN, Harter HR. Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysis. Kidney Int. 1982;21:862–7.PubMedGoogle Scholar
  188. 188.
    Cannata JB, Briggs JD, Fell GS, Junor BJR. Comparison of control serum phosphate levels during continuous ambulatory peritoneal dialysis and during hemodialysis. Pert Dial Bull. 1983;3:97–8.Google Scholar
  189. 189.
    Fleming LW, Hudson SW, Stewart WK. Improved phosphate clearances with polycarbonate membranes. Clin Exp Dialysis Apheresis. 1982;6:211–22.Google Scholar
  190. 190.
    Miller JH, Gardner PW, Heinekin F, Samar R, Shinaberger JH. Studies of inorganic phosphate removal during acetate and bicarbonate dialysis. Proc Am Soc Artif Intern Organs. 1983;12:57.Google Scholar
  191. 191.
    Kobrin SM, Goldstein SJ, Shangraw RF, Raja RM. Variable efficacy of calcium carbonate tablets. Am J Kidney Dis. 1989;14:461–5.PubMedGoogle Scholar
  192. 192.
    Llach F, Nikakhtar B. Methods of controlling hyperphosphatemia in patients with chronic renal failure. Curr Opin Nephrol Hypertens. 1993;2:365–71.PubMedGoogle Scholar
  193. 193.
    Clarkson EM, McDonald SJ, De Wardener H. The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin Sci. 1966;30:425.PubMedGoogle Scholar
  194. 195.
    Malluche HH, Werner E, Ritz E. Intestinal absorption of calcium and whole body calcium retention in incipient and advanced renal failure. Mineral Electrolyte Metab. 1978; 1:264.Google Scholar
  195. 196.
    Ginsberg DS et al. Hypercalcemia after oral calcium carbonate therapy in patients on chronic hemodialysis. Lancet. 1973;1:1271.Google Scholar
  196. 197.
    Meyrier A, Marsac J, Richet G. The influence of a high calcium carbonate intake on bone disease in patients undergoing hemodialysis. Kidney Int. 1973;4:146–53.PubMedGoogle Scholar
  197. 198.
    Johnson WJ. Optimum dialysate calcium concentration during maintenance hemodialysis. Nephron. 1978;17: 241–58.Google Scholar
  198. 199.
    Raman A, Chong YK, Sreenevasan G. Effects of varying dialysate calcium concentration on the plasma calcium fractions in patients on dialysis. Nephron. 1976;16:181–8.PubMedGoogle Scholar
  199. 200.
    Llach F, Coburn JW. Renal osteodystrophy and maintenance dialysis. In: Maher JF, editor. Replacement of Renal Function by Dialysis. Dordrecht: Kluwer, 1989:911.Google Scholar
  200. 201.
    Fernandez E, Montoliu J. Successful treatment of massive uremic tumoral calcinosis with daily haemodialysis and very low calcium dialysate. Nephrol Dial Transplant. 1994;9: 1207–9.PubMedGoogle Scholar
  201. 202.
    Goldsmith RS. The effects of calcium and phosphorus in hemodialysis. Annu Rev Med. 1976;27:181–90.PubMedGoogle Scholar
  202. 203.
    Bender FH, Bernardini J, Piraino B. Calcium mass transfer with dialysate containing 1.25 and 1.75 mmol/L calcium in peritoneal dialysis patients. Am J Kidney Dis. 1992;20: 367–71.PubMedGoogle Scholar
  203. 203a.
    Millner DS, Lieberman E, Landin B. Soft tissue calcification in pediatric patients with ESRD. Kidney Int. 1990;38:931–6.Google Scholar
  204. 204.
    Cunningham J, Beer J, Coldwell RD, Noonan K, Sawyer N, Makin HL. Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol. Nephrol Dial Transplant. 1992;7:63–8.PubMedGoogle Scholar
  205. 205.
    Johnson DW, Rigby RJ, McIntyre HD, Brown A, Freeman J. A randomized trial comparing 1.25 mmo1/1 calcium dialysate to 1.75 mmo1/1 calcium dialysate in CAPD patients. Nephrol Dial. 1996;11:88–93.Google Scholar
  206. 206.
    Weinreich T, Passlick-Deetjen J, Ritz E. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group. Am J Kidney Dis. 1995;25: 452–60.PubMedGoogle Scholar
  207. 207.
    Cohen EP, Moulder JE. Parathyroidectomy in chronic renal failure: has medical care reduced the need for surgery? Nephron. 2001;89:271–3.PubMedGoogle Scholar
  208. 208.
    Witmer G, Margolis A, Fontaine O et al. Effects of 25 hydroxycholecalciferol on bone lesions of children with terminal renal failure. Kidney Int. 1976;10:395–408.PubMedGoogle Scholar
  209. 209.
    Recker R, Schoenfeld P, Letteri JM, Slatopolsky E, Goldsmith R, Brickman AS. The efficacy of calcifediol in renal osteodystrophy. Arch Intern Med. 1978;138:857–66.PubMedGoogle Scholar
  210. 210.
    Cunningham J, Makin H. How important is vitamin D deficiency in uraemia? Nephrol Dial Transplant. 1997;12: 16–18.PubMedGoogle Scholar
  211. 211.
    Coburn JW, Brickman AS, Sherrard DJ. Clinical efficacy of 1,25 dihydroxyvitamin D3 in renal osteodystrophy. In: Norman AW, Schaeffer K, Coburn JW, editors. Vitamin D: Biochemical, Chemical and Clinical Aspects Related to Calcium Metabolism. Berlin: de Gruyter, 1977:657.Google Scholar
  212. 212.
    Berl T, Berns AS, Hufer WE et al. 1,25 Dihydrox-ycholecalciferol effects in chronic dialysis. A double-blindcontrolled study. Ann Intern Med. 1978;88:774–80.PubMedGoogle Scholar
  213. 213.
    Goodman WG, Coburn JW. The use of 1,25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med. 1992; 43:227–37.PubMedGoogle Scholar
  214. 214.
    Ritz E, Kuster S, Schmidt-Gayk H et al. Low dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphate. Prospective placebo controlled multicenter trial. Nephrol Dial Transplant. 1995;10:2228–34 (abstract).PubMedGoogle Scholar
  215. 215.
    Christiansen C, Rodbro P, Christensen MS, Hartnack B, Transbol I. Deterioration of renal function during treatment of chronic renal failure with 1,25 dihydroxycholecalciferol. Lancet. 1978;2:700–3.PubMedGoogle Scholar
  216. 216.
    Bertoli M, Luisetto G, Ruffatti A, Urso M, Romagnoli G. Renal function during calcitriol therapy in chronic renal failure. Clin Nephrol. 1990;33:98–102.PubMedGoogle Scholar
  217. 217.
    Cunningham J. The prevention of secondary hyperparathyroidism. Curr Opin Nephrol Hypertens. 1993;2:552–7.PubMedGoogle Scholar
  218. 218.
    Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis. 1997;29:496–502.PubMedGoogle Scholar
  219. 219.
    Dunlay R, Rodriguez M, Felsenfeld AJ, Llach F. Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis patients. Kidney Int. 1989;36: 1093–8.PubMedGoogle Scholar
  220. 220.
    Gallieni M, Brancaccio D, Padovese P et al., Italian Group for the Study of Intravenous Calcitriol. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int. 1992;42:1191–8.PubMedGoogle Scholar
  221. 221.
    Andress DL, Norris KC, Coburn JW, Slatopolsky E, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med. 1989;321:274–9.PubMedGoogle Scholar
  222. 222.
    Reichel H, Szabo A, Uhl J et al. Intermittent versus continuous administration of 1,25(OH)2D3 in experimental renal hyperparathyroidism. Kidney Int. 1993;44:1259–65.PubMedGoogle Scholar
  223. 223.
    Fernandez E, Llach F. Guidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism. Nephrol Dial. 1996;11:96–101.Google Scholar
  224. 224.
    Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25 dihydroxycholecalciferol in uremic patients. J Clin Invest. 1984; 74:2136–43.PubMedGoogle Scholar
  225. 225.
    Hamdy NAT, Brown C, Kanis JA. Intravenous calcitriol lowers serum calcium concentrations in uraemic patients with severe hyperparathyroidism and hypercalcemia. Nephrol Dial Transplant. 1989;4:545–8.PubMedGoogle Scholar
  226. 226.
    Cannella G, Bonucci E, Rolla D et al. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int. 1994;46:1124–32.PubMedGoogle Scholar
  227. 227.
    Dressler R, Laut J, Lynn R, Ginsberg N. Long term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism. Clin Nephrol. 1995;43:324–31.PubMedGoogle Scholar
  228. 228.
    Llach F, Hervas J, Cerezo S. The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism. Am J Kidney Dis. 1995;26:845–51.PubMedGoogle Scholar
  229. 229.
    Muramoto H, Haruki K, Yoshimura A, Mimo N, Oda K, Tofuku Y. Treatment of refractory hyperparathyroidism in patients on hemodialysis by intermittent oral administration of 1, 25(OH)2 vitamin d3. Nephron. 1991;58:288–94.PubMedGoogle Scholar
  230. 230.
    Fukagawa M, Orazaki R, Takano K et al. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med. 1990;323:421–2.PubMedGoogle Scholar
  231. 231.
    Quarles LD, Yohay DA, Carroll BA et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. 1994;45:1710–21.PubMedGoogle Scholar
  232. 232.
    Song MM, Levine BS. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol. 1996;7:488–96.PubMedGoogle Scholar
  233. 233.
    Herrmann P, Ritz E, Schmidt-Gayk H et al. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial. Nephron. 1994;67:48–53.PubMedGoogle Scholar
  234. 234.
    Delmez JA, Dougan CS, Gearing BK et al. The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int. 1987;31:795–9.PubMedGoogle Scholar
  235. 235.
    Vieth R, Ledermann SE, Kooh SW, Balfe JW. Losses of calcitriol to peritoneal dialysis bags and tubing. Pert Dial Int. 1989;9:277–80.Google Scholar
  236. 236.
    Jones CL, Vieth R, Spino M et al. Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. Clin Nephrol. 1994;42:44–9.PubMedGoogle Scholar
  237. 237.
    Torregrosa JV, Campistol JM, Mas M, Montesinos M, Martinez De Osaba MJ. Usefulness and pharmacokinetics of subcutaneous calcitriol in the treatment of secondary hyperparathyroidism. Nephrol Dial Transplant. 1996;11: 54–7.PubMedGoogle Scholar
  238. 238.
    Brown AJ. Vitamin D analogues. Am J Kidney Dis. 1998;32:S25–39.PubMedGoogle Scholar
  239. 239.
    Slatopolsky EA, Finch J, Denda M, Morrissey J, Brown A, DeLuca H. A new analog of calcitriol, 19-nor-1,25(OH)3D2 suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis. 1995;26:852–60.PubMedGoogle Scholar
  240. 240.
    Llach F, Keshav G, Goldblat MV et al. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue. 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis. 1998;32:D48–54.Google Scholar
  241. 241.
    Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-nor- 1-α-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact PTH in patients on hemodialysis. J Am Soc Nephrol. 1998;9:1427–32.PubMedGoogle Scholar
  242. 242.
    Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism Am J Kidney Dis. 2001;38(Supp1.5)S:45–50.Google Scholar
  243. 243.
    Tan AUJ, Levine BS, Mazess RB et al. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int. 1997;51:317–23.PubMedGoogle Scholar
  244. 244.
    Sjoden G, Lindgren JU, DeLuca HF. Antirachitic activity of 1 α-hydroxyergolcalciferol and 1 α-hydroxcholecalciferol. J Nutr. 1984;114:2043–6.PubMedGoogle Scholar
  245. 245.
    Sjoden G, Smith C, Lindgren JU et al. 1 α-Hydroxyvitamin D2 is less toxic than 1 α-hydroxyvitamin D3 in the rat. Proc Soc Exp Biol Med. 1985;178:432–6.PubMedGoogle Scholar
  246. 246.
    Gallagher JC, Bishop CW, Knutson JC et al. Effects of increasing doses of 1 α-hydroxyvitamin D2 on calcium homeostasis in post-menopausal osteopenic women. J Bone Miner Res. 1994;9:607–14.PubMedGoogle Scholar
  247. 247.
    Weber K, Goldberg M, Stanganssinger M, Erben RG. 1 Alpha-hydroxyvitamin D2 is less toxic but not bone selectivity relative to 1 alpha-hydroxyvitamin D3 in ovariectimized rats. J Bone Miner Res. 2001;16:639–51.PubMedGoogle Scholar
  248. 248.
    rats hectorolGoogle Scholar
  249. 249.
    Frazao JM, Chesney RW, Coburn JW. Intermittent oral 1 alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1 alphaD2 Study Group. Nephrol Dial Transplant. 1998;13:68–72.PubMedGoogle Scholar
  250. 250.
    Maung HM, Elangovan L, Frazao JM et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol in dialysis patients with secondary hyperparathyoidism: a sequential comparison. Am J Kidney Dis. 2001;37:532–43.PubMedGoogle Scholar
  251. 251.
    Walker GS, Peacock M, Aaron J, Robinson PJ, Davison AM. Prophylactic 1 alpha-hydroxyvitamin D3 therapy in haemodialysis patients. Clin Endocrinol. 1977;7:125–30s.Google Scholar
  252. 252.
    Pierides AM, Kerr DNS, Ellis HA. 1 α-Hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy. Clin Nephrol. 1976;5: 189–92.Google Scholar
  253. 253.
    Peacock M. The clinical uses of lα-hydroxyvitamin D3. Clin Endocrinol. 1977;7(Suppl.):1–246s.Google Scholar
  254. 254.
    Brandi L, Daugaard H, Tvedegaard E, Storm T, Olgaard K. Effects of intravenous 1α(OH)D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis. Nephron. 1989;53:194–200.PubMedGoogle Scholar
  255. 255.
    Lind L, Wengle B, Wide L, Srege U, Ljunghall S. Suppres-sion of serum parathyroid hormone levels by intravenous alphacalcidol in uremic patients on maintenance hemodialysis. Nephron. 1988;48:296–9.PubMedGoogle Scholar
  256. 256.
    Nemeth EF. Calcium receptors as novel drug targets. In: Bikezikian JP, Raisz LG, Rodan GA, editors. Principles in Bone Biology. New York: Academic Press, 1996: 1019–35.Google Scholar
  257. 257.
    Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int. 2001;59: 1187–201.PubMedGoogle Scholar
  258. 258.
    Brown EM, Pollack M, Herbert SC. The extracellular calcium sensing receptor: its roles in health and disease. Annu Rev Med. 1998;49:15–29.PubMedGoogle Scholar
  259. 259.
    Brown EM. Physiology and pathophysiology of the extracellular calcium-sensing receptor. Am J Med. 1999;106: 238–53.PubMedGoogle Scholar
  260. 260.
    Brown EM. The extracellular Ca sensing regulation of parathyroid cell function, and the role of Ca and other ions as extracellular (first) messengers. Physiol Rev. 1991;71: 371–411.PubMedGoogle Scholar
  261. 261.
    Hebert SC. Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Kidney Int. 1996;50:2129–39.PubMedGoogle Scholar
  262. 262.
    Pearce SHS, Williamson C, Kifor O et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med. 1996;335: 1115–22.PubMedGoogle Scholar
  263. 263.
    Pollak MR, Brown EM, Estep HL et al. Autosomal dominant hypocalcaemia caused by a Ca sensing receptor gene mutation. Nat Genet. 1994;8:303–7.PubMedGoogle Scholar
  264. 264.
    Heath DA. Familial hypocalciuric hypercalcemia. In: Bilezimian JP, Levine MA, Marcus R, editors. The Parathryoids. New York: Raven Press, 1994:699–710.Google Scholar
  265. 265.
    Pollak MR, Seidman CE, Brown EM. Mutations in the human Ca sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathroidism. Cell. 1997;75:1297–303.Google Scholar
  266. 266.
    Connor DA, Pollak MR, Ladd DJ et al. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet. 1995;11:389–94.Google Scholar
  267. 267.
    Nemeth EF. Ca receptor-dependent regulation of cellular functions. News Physiol Sci. 1995;10:1–5.Google Scholar
  268. 268.
    Wada M, Furuya Y, Sakiyama J. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency: control of parathyoid cell growth via a calcium receptor. J Clin Invest. 1997;100:2977–83.PubMedGoogle Scholar
  269. 269.
    Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int. 2000;58:436–45.PubMedGoogle Scholar
  270. 270.
    Antonsen JE, Sherrard, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int. 1998;53:223–7.PubMedGoogle Scholar
  271. 271.
    Fukagawa M, Kitaoka M, Kurokawa K. Ultrasonographic intervention of parathyroid hyperplasia in chronic dialysis patients: a theoretical approach. Nephrol Dial Transplant. 1996;11:125–9.PubMedGoogle Scholar
  272. 272.
    Giangrande A, Castiglioni A, Solbiati L, Allaria P. Ultrasound-guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Nephrol Dial Transplant. 1992;7:412–21.PubMedGoogle Scholar
  273. 273.
    Giangrande A, Cantu P, Solbiati L, Ravetto C. Ultrasonically guided fine-needle alcohol injection as an adjunct to medical treatment in secondary hyperparathyroidism. Proc Eur Dial Transplant Assoc. 1984;21:895–901.Google Scholar
  274. 274.
    Kitaoka M, Fukagawa M, Ogata E, Kurokawa K. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int. 1994;46: 1110–17.PubMedGoogle Scholar
  275. 275.
    Kitaoka M, Fukagawa M, Kurokawa K. Direct injection of calcitriol into parathyroid hyperplasia in chronic dialysis patients with severe parathyroid hyperfunction. Nephrology. 1995;1:563–8.Google Scholar
  276. 276.
    Llach F. Parathyroidectomy in chronic renal failure: indications, surgical approach and the use of calcitriol. Kidney Int. 1990;38:S62–8.Google Scholar
  277. 277.
    Ellis HA. Fate of long term parathyroid autografts in patients with chronic renal failure treated by parathyroidectomy: a histopathological study of autografts, parathyroid glands and bone. Histopathology. 1988;13: 289–309.PubMedGoogle Scholar
  278. 278.
    Chesser AM, Carroll MC, Lightowler C, Macdougall IC, Britton KE, Baker LR. Technetium-99m methoxy isobutyl isonitrile (MIBI) imaging of the parathyroid glands in patients with renal failure. Nephrol Dial Transplant. 1997;12:97–100.PubMedGoogle Scholar
  279. 279.
    Stehman-Breen C, Muirhead N, Thirning D, Sherrard D. Secondary hyperparathyroidism complicated by parathyromatosis. Am J Kidney Dis. 1996;28:502–7.PubMedGoogle Scholar
  280. 280.
    Tominaga Y, Tanaka Y, Sato K, Nagasaka T, Takagi H. Histopathology, pathophysiology and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol. 1997;13:78–86.PubMedGoogle Scholar
  281. 281.
    Gagne ER, Urena P, Leite-Silva S et al. Short- and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol. 1992;3: 1008–17.PubMedGoogle Scholar
  282. 282.
    White JV, Logerfo P, Feind C, Weber C. Autologous parathyroid transplantation. Lancet. 1983;2:461–5.PubMedGoogle Scholar
  283. 283.
    Kaye M, D ’Amour P, Henderson J. Elective total parathyroidectomy without autotransplant in end-stage renal disease. Kidney Int. 1989;35:1390–9.PubMedGoogle Scholar
  284. 284.
    Felsenfeld AJ, Gutman RA, Llach F. Postparathyroidectomy hypocalcemia as an accurate indicator of preparathyroidectomy bone histology in the uremic patient. Mineral Electrolyte Metab. 1984;10:166–72.Google Scholar
  285. 285.
    Litchman MB, Kinder BK, Johnson BM. Calcium requirements in ESRD patients after total parathyroidectomy with autotransplantation. Dial Transplant. 1987;16:611–16.Google Scholar
  286. 286.
    Benz RL, Schleifer CR, Teehan BP et al. Successful treatment of postparathyroidectomy hypocalcemia using continuous ambulatory intraperitoneal calcium (CAIC) therapy. Pert Dial Int. 1989;9:285–90.Google Scholar
  287. 287.
    Thule P, Thakore K, Vansant J, McGarity W, Weber C, Phillips LS. Preoperative localization of parathyroid tissue with technetium-99m sestamibi 1231 subtraction scanning. J Clin Endocrinol Metab. 1994;78:77–82.PubMedGoogle Scholar
  288. 288.
    Caixas A, Berna L, Piera J et al. Utility of 99mTc-sestamibi scintigraphy as a first-line imaging procedure in the preoperative evaluation of hyperparathyroidism. Clin Endocrinol. 1995;43:525–30.Google Scholar
  289. 289.
    Shpitz B, Korzets Z, Dimbar A, Jedeikin R, Hoffman MB, Bernheim J. Immediate post-operative management of parathyroidectomy hemodialyzed patients. Dial Transplant. 1986;15:507–13.Google Scholar
  290. 290.
    Hercz G, Pei Y, Greenwood C et al. Aplastic osteodystrophy without aluminum: the role of ‘suppressed’ parathyroid function. Kidney Int. 1993;44:860–6.PubMedGoogle Scholar
  291. 291.
    Montenegro J, Saracho R, Gonzalez O, Moina I, Martinez I. Reversibility of parathyroid gland suppression in CAPD patients with low i-PTH levels. Clin Nephrol. 1997;48: 359–63.PubMedGoogle Scholar
  292. 292.
    Delano BG, Baker R, Gardner B, Wallach S. A trial of calcitonin therapy in renal osteodystrophy. Nephron. 1973; 11:287–93.PubMedGoogle Scholar
  293. 293.
    Fleisch H, Russell RGC, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969;165:1262–4.PubMedGoogle Scholar
  294. 294.
    Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 1993;00:000–000.Google Scholar
  295. 295.
    Malluche HH. The possible use of bisphosphonates in the treatment of renal osteodystrophy. Clin Nephrol. 1992; 38:(Supp1.1):S87–91.PubMedGoogle Scholar
  296. 296.
    Henderson RG, Russell RGG, Earnshaw M, Ledingham JG, Oliver DO, Woods CG. Loss of metacarpal and iliac bone in chronic renal failure: influence of haemodialysis, parathyroid activity, type of renal disease, physical activity and heparin consumption. Clin Sci. 1979;56:317–24.PubMedGoogle Scholar
  297. 297.
    Griffith GC, Nichols G, Asher JD, Flanagan B. Heparin osteoporosis. J Am Med Assoc. 1996;195:1089.Google Scholar
  298. 298.
    Jaffe MD, Wellis PW. Multiple fractures associated with long term sodium heparin therapy. J Am Med Assoc. 1965;193:152.Google Scholar
  299. 299.
    Majdalani G, Chomant J, Kachko A, Yanai M, Man NK. Kinetics of technetium-labeled heparin in hemodialyzed patients. Kidney Int. 1993;43(Supp1.41):S131–4.Google Scholar
  300. 300.
    Llach F, Goldblatt MV, Freundlich RE, Ganess M, Griffith WH, Yudd M. The evolving pattern of calcemic uremic arteriolopathy. J Am Soc Nephrol.1982;109:85–95Google Scholar
  301. 301.
    Chan YL, Mahoney JF, Turner JJ, Posen S. The vascular lesions assoicated with skin necrosis in renal disease. Br J Dermatol. 1983;109:85–95.PubMedGoogle Scholar
  302. 302.
    Budisavijevic MN, Chiik D, Ploth DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol. 1996;7:978–82.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2004

Authors and Affiliations

  • Francisco Llach
  • Francisco Velasquez-Forero

There are no affiliations available

Personalised recommendations